View in EDS

A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.

Saved in:
Bibliographic Details
Title: A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.
Authors: Richardson PG; aJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Perrot A; bCHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France., San-Miguel J; cCancer Center Clínica Universidad de Navarra, Navarra, CCUN, CIMA,IDISNA, CIBER-ONC, Pamplona, Spain., Beksac M; dDepartment of Hematology, Ankara University, Ankara, Turkey., Spicka I; eGeneral Faculty Hospital, Prague, Czech Republic.; fFirst Faculty of Medicine, Charles University, Prague, Czech Republic., Leleu X; gService d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France., Schjesvold F; hOslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway.; iKG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Moreau P; jHematology Department, CHU Nantes, Nantes, France., Dimopoulos MA; kDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.; lDepartment of Medicine, Korea University, Seoul, South Korea., Huang SY; mDepartment of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Minarik J; nDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc,Olomouc, Czech Republic., Cavo M; ooIRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, and the Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy., Prince HM; pImmunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia., Anderson KC; hOslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway.
Source: Future oncology (London, England) [Future Oncol] 2025 Mar; Vol. 21 (6), pp. 653-663. Date of Electronic Publication: 2025 Jan 24.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39851267
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; aJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Perrot+A%22">Perrot A</searchLink>; bCHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22San-Miguel+J%22">San-Miguel J</searchLink>; cCancer Center Clínica Universidad de Navarra, Navarra, CCUN, CIMA,IDISNA, CIBER-ONC, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Beksac+M%22">Beksac M</searchLink>; dDepartment of Hematology, Ankara University, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Spicka+I%22">Spicka I</searchLink>; eGeneral Faculty Hospital, Prague, Czech Republic.; fFirst Faculty of Medicine, Charles University, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; gService d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France.<br /><searchLink fieldCode="AU" term="%22Schjesvold+F%22">Schjesvold F</searchLink>; hOslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway.; iKG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Moreau+P%22">Moreau P</searchLink>; jHematology Department, CHU Nantes, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; kDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.; lDepartment of Medicine, Korea University, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Huang+SY%22">Huang SY</searchLink>; mDepartment of Hematology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Minarik+J%22">Minarik J</searchLink>; nDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc,Olomouc, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Cavo+M%22">Cavo M</searchLink>; ooIRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, and the Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Prince+HM%22">Prince HM</searchLink>; pImmunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Anderson+KC%22">Anderson KC</searchLink>; hOslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2025 Mar; Vol. 21 (6), pp. 653-663. <i>Date of Electronic Publication: </i>2025 Jan 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39851267
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2025.2449781
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 653
    Titles:
      – TitleFull: A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Richardson PG
      – PersonEntity:
          Name:
            NameFull: Perrot A
      – PersonEntity:
          Name:
            NameFull: San-Miguel J
      – PersonEntity:
          Name:
            NameFull: Beksac M
      – PersonEntity:
          Name:
            NameFull: Spicka I
      – PersonEntity:
          Name:
            NameFull: Leleu X
      – PersonEntity:
          Name:
            NameFull: Schjesvold F
      – PersonEntity:
          Name:
            NameFull: Moreau P
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Huang SY
      – PersonEntity:
          Name:
            NameFull: Minarik J
      – PersonEntity:
          Name:
            NameFull: Cavo M
      – PersonEntity:
          Name:
            NameFull: Prince HM
      – PersonEntity:
          Name:
            NameFull: Anderson KC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2025 Mar
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1